Oncology, Vaccine Reaction
Conditions
Keywords
covid-19, vaccine, pet/ct, FDG, mRNA
Brief summary
It is important to evaluate the vaccine-related metabolic changes on FDG PET/CT to avoid confusing results. The investigators aimed to assess the frequency and intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine (BNT162b2-Pfizer/BioNTech) and to analyze possible factors affecting these changes.
Interventions
DIAGNOSTIC_TESTF-18 FDG PET/CT imaging
Oncological imaging
BIOLOGICALPfizer/biontech mRNA vaccine
COVID-19 vaccine
Sponsors
Kocaeli University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients referred for post-vaccination FDG PET/CT imaging
Exclusion criteria
* Disseminated metastatic disease, ipsilateral breast cancer or lymphoma that was likely to involve axilla, and patients who had ipsilateral intense axillary uptake or thyroiditis on their prior imaging, were
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| to assess the frequency of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine | 5 month | Frequency of metabolic changes |
| to assess the FDG intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine | 5 month | FDG intensity of metabolic changes |
Countries
Turkey (Türkiye)
Outcome results
None listed